Don Davies on Questions Passed as Orders for Returns

With regard to Health Canada’s authorization of the Comirnaty Omicron XBB.1.5 and Spikevax XBB.1.5 vaccines: (a) is there any clinical data demonstrating efficacy of these vaccines, and, if so, what data; (b) is there any clinical data demonstrating safety of these vaccines, and, if so, what data; (c) is there any data suggesting that previously authorized messenger ribonucleic acid (mRNA) vaccines are outdated with respect to currently circulating variants of the SARS-CoV-2 virus; (d) is there any concern that currently authorized mRNA vaccines will help select for more successful variants of the SARS-CoV-2 virus; (e) is there any data suggesting that disease-induced immunity is stronger than vaccine-induced immunity from authorized mRNA vaccines for COVID-19; (f) do currently authorized mRNA vaccines prevent COVID-19 infection; (g) do currently authorized mRNA vaccines prevent COVID-19 transmission; and (h) what positive health impact do currently authorized mRNA vaccines have on recipients?